GT Biopharma, Inc.

NasdaqCM:GTBP Stock Report

Market Cap: US$6.7m

GT Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GTBP?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders159,5787.14%
Hedge Funds190,0008.5%
General Public204,0449.13%
Public Companies219,4579.82%
Institutions1,461,24965.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.8%.

Top Shareholders

Top 25 shareholders own 90.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
51.7%
Deka Investment GmbH
1,154,867US$3.5m18%no data
9.82%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
219,457US$658.4k139%no data
8.5%
Bristol Capital Advisors LLC
190,000US$570.0k0%3.52%
4.82%
Richard Ziman
107,617US$322.9k0%no data
4.82%
Armistice Capital LLC
107,617US$322.9k0%0.01%
4.82%
The Rosalinde Arthur Gilbert Foundation Endowment Arm
107,617US$322.9k0%no data
1.34%
BMO Asset Management Corp.
29,872US$89.6k0%no data
1.28%
Michael Breen
28,540US$85.6k0%no data
0.67%
Geode Capital Management, LLC
15,041US$45.1k34.5%no data
0.53%
Bruce Wendel
11,755US$35.3k0%no data
0.52%
Manu Ohri
11,666US$35.0k0%no data
0.47%
The Vanguard Group, Inc.
10,504US$31.5k0%no data
0.45%
Susquehanna International Group, LLP, Asset Management Arm
10,105US$30.3k-46.8%no data
0.45%
Wells Fargo & Company, Securities and Brokerage Investments
10,013US$30.0k0%no data
0.44%
BlackRock, Inc.
9,737US$29.2k-0.32%no data
0.17%
UBS Asset Management AG
3,903US$11.7k-56.5%no data
0.074%
Tower Research Capital Europe Limited
1,643US$4.9k-24.4%no data
0.012%
Morgan Stanley, Investment Banking and Brokerage Investments
266US$798.30%no data
0.00076%
Bank of America Corporation, Asset Management Arm
17US$50.954.6%no data
0.00045%
Blue Bell Private Wealth Management, LLC
10US$30.20%no data
0.00045%
Merrill Lynch & Co. Inc., Banking Investments
10US$30.2-37.5%no data
0.00031%
Osaic Wealth, Inc. , Asset Management Arm
7US$20.80%no data
0.00027%
BNP Paribas Arbitrage Sa, Asset Management Arm
6US$18.10%no data
0.00022%
City National Rochdale, LLC
5US$14.70%no data
0.00022%
Arbor Point Advisors, LLC
5US$14.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 02:41
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GT Biopharma, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin WalshB. Riley Securities, Inc.
Charles ButlerRoth MKM
Jonathan AschoffRoth MKM